Roche Diagnostics is gearing up for a slew of new product launches in 2024, which will make it “the biggest launch year for diagnostics in the division’s history,” Roche CEO Thomas Schinecker said on a conference call discussing the company’s 2023 financials.

 Fully automated mass spectrometry system

Roche Diagnostics CEO Matt Sause has said several times in 2024 that Roche Diagnostics’ I601 fully automated mass spectrometry system will be integrated with Roche’s existing serum workspace instrumentation “to make us more competitive in our core laboratories.”

The new fully automated clinical analyzer, based on mass spectrometry technology, will be launched in 2024, first in the EU and then in the US and China. It will be integrated into Roche’s existing Cobas Pro Integrated Solutions analyzer, a clinical chemistry and immunochemistry analyzer for medium- to high-throughput laboratories.

Cobas c703 and Cobas ISE Neo

The company also plans to launch its Cobas c703 high-throughput clinical chemistry solution and Cobas ISE Neo solution to “maintain our strong momentum in core laboratories,” Sause said.

The Cobas c703 is a high-throughput clinical chemistry analyzer from Roche Diagnostics designed to meet the needs of high-volume medical laboratories. It is part of the Cobas 8000 modular analyzer series, which is designed for clinical chemistry testing, including a wide range of assays such as blood biochemistry, electrolyte balance, enzyme activity assays, and specific protein assays.

The Cobas ISE Neo is a dedicated electrolyte analysis device from Roche Diagnostics designed to provide clinical laboratories with a fast and accurate solution for electrolyte testing.ISE (Ion Selective Electrode) technology is a method used to measure the concentration of specific ions in a solution, and the Cobas ISE Neo uses This technology analyzes electrolytes in blood, urine or other biological samples.

Respiratory Multi-Test

In the U.S., Roche plans to launch its Liat (Laboratory in a tube) multiplex molecular respiratory viral assay for influenza A/B, COVE-19 and respiratory syncytial virus. Roche also plans to launch a respiratory panel on the COBA 5800, 6800, 8800, and 8800 molecular instruments to detect a broad range of respiratory pathogens using its new temperature-assisted generation of signaling chemistry.

Regarding the new crown test, Sause said Roche Diagnostics has a $300 million government order for rapid antigen testing in the fourth quarter of 2023, but does not anticipate any more government orders or significant antigen test sales. He added that he believes the vast majority of new crown tests will come from PCR-based multiplex testing.

In large molecular laboratories, PCR analysis can be performed on multiple samples at the same time-a multistep process that requires a skilled technician. cobas® Liat systems fully automate these steps for rapid analysis of a single sample, making them ideal for time-sensitive in-clinic diagnostics without operator intervention or interpretation.

Cobas 6800/8800

Roche will launch a second version of its high-throughput Cobas 6800/8800 instrument in 2024, which will include additional functionality and “competitive features,” Sause said.

The second edition is an upgrade based on existing Cobas 6800/8800 systems that are designed to meet the demands of high-throughput molecular diagnostics, delivering fast, accurate results for labs of all sizes.

Malaria molecular detection products

Roche also expects to launch a malaria molecular test that will detect all five species of Plasmodium that occur in humans and will be used to screen blood donors, blood products, organs and tissues.

Continuous glucose monitoring solutions

Roche Diagnostics diabetes care sales declined 14% from CHF 1.6 billion in 2022 to CHF 1.37 billion in 2023.

The diabetes decline is being driven by a market shift from traditional glucose monitoring to continuous glucose monitoring, but Roche plans to launch its own continuous glucose monitoring solution in 2024 and hopes to “change this trend in the future.”

Roche Diagnostics 2024 to look forward to

Roche Diagnostics is gearing up for the biggest product launch year in its history, a move that is expected to further solidify its position as a global leader in diagnostics.Roche expects to see mid- to high-single-digit growth in diagnostics in 2024, Sause said.

The 2024 new product program demonstrates Roche’s deep strength in delivering innovative, efficient and accurate diagnostics. With these advanced diagnostic solutions, Roche is not only addressing the challenges facing clinical laboratories today, but also setting new standards for future healthcare trends.

With the launch of these new products, Roche Diagnostics will lead the diagnostic industry to move forward and provide better healthcare services to patients around the world. This not only reflects Roche’s positive outlook on the future of healthcare, but also strengthens its competitiveness in the global diagnostics market.